SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Stokstad ELR. Historical perspective on key advances in the biochemistry and physiology of folates. In: PiccianoMF, StokstadELR, Gregory, JF, editors. Folic acid metabolism in health and disease. New York: Wiley-Liss, 1990: 121.
  • 2
    Jansen G. Receptor-and carrier-mediated transport systems for folates and antifolates. In: JackmanAL, editor. Antifolate drugs: basic research and clinical practice. Totowa, NJ: Humana Press Inc., 1999: 293321.
  • 3
    Matherly LH, Goldman ID. Membrane transport of folates. Vitam Horm. 2003; 66: 403456.
  • 4
    Ferguson PL, Flintoff WF. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J Biol Chem. 1999; 274: 1626916278.
  • 5
    Liu XY, Matherly LH. Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochem Pharmacol. 2002; 1564: 333342.
  • 6
    Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci. 1971; 186: 400422.
  • 7
    Henderson GB, Zevely EM. Anion exchange mechanism for transport of methotrexate in L1210 cells. Biochem Biophys Res Commun. 1981; 99: 163169.
  • 8
    Zhao R, Gao F, Wang Y, Diaz GA, Gelb BD, Goldman ID. Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem. 2001; 276: 11141118.
  • 9
    Flintoff WF, Nagainis CR. Transport of methotrexate in Chinese hamster ovary cells: a mutant defective in methotrexate uptake and cell binding. Arch Biochem Biophys. 1983; 223: 433440.
  • 10
    Assaraf YG, Schimke RT. Identification of methotrexate transport deficiency in mammalian cells using fluoresceinated methotrexate and flow cytometry. Proc Natl Acad Sci USA. 1987; 84: 71547158.
  • 11
    Schuetz JD, Matherly LH, Westin EH, Goldman ID. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line. J Biol Chem. 1988; 263: 98409847.
  • 12
    Brigle KE, Spinella MJ, Sierra EE, Goldman ID. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem. 1995; 270: 2297422979.
  • 13
    Gong M, Yess J, Connoly T, et al. Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Blood. 1997; 89: 24942499.
  • 14
    Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem. 1998; 273: 3018930198.
  • 15
    Wong S, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem. 1999; 274: 1038810394.
  • 16
    Drori S, Jansen G, Mauritz R, Peters GJ, Assaraf YG. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem. 2000; 275: 3085530863.
  • 17
    Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cells. Biochem J. 2002; 367: 741750.
  • 18
    Zhao R, Assaraf YG, Goldman ID. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem. 1998; 273: 78737879.
  • 19
    Zhao R, Assaraf YG, Goldman ID. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate and an obligatory anion requirement for transport function. J Biol Chem. 1998; 273: 1906519071.
  • 20
    Tse A, Brigle KE, Taylor SM, Moran RG. Mutations in the reduced folate carrier which confer dominant resistance to 5,10-dideazatetrahydrofolate. J Biol Chem. 1998; 273: 2595325960.
  • 21
    Zhao R, Sharina IG, Goldman ID. Pattern of mutations that results in loss of a reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol Pharmacol. 1999; 56: 6876.
  • 22
    Zhao R, Gao F, Wang P-J, Goldman ID. Role of amino acid 45 residue in reduced folate carrier function and anion-dependent transport as characterized by site-directed mutagenesis. Mol Pharmacol. 2000; 57: 317323.
  • 23
    Rothem L, Aronheim A, Assaraf YG. Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem. 2003; 278: 89358941.
  • 24
    Rothem L, Stark M, Kaufman Y, Mayo L, Assaraf YG. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J Biol Chem. 2004; 279: 374384.
  • 25
    Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res. 1981; 41: 44474452.
  • 26
    Gorlick R, Goker E, Trippett T, Waltham MC, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med. 1996; 335: 10411048.
  • 27
    Trippett T, Schlemmer S, Elisseyef Y, et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood. 1992; 80: 11581162.
  • 28
    Gorlick R, Goker E, Trippet T, et al. Defective transport is a common mechanism of acquired resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood. 1997; 89: 10131018.
  • 29
    Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly LH. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia—relationship to immunophenotype and ploidy. Clin Cancer Res. 1998; 4: 21692177.
  • 30
    Belkov VM, Krynetski EY, Schutetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not for lineage differences in methotrexate accumulation. Blood. 1999; 93: 16431650.
  • 31
    Jansen G, Kathmann I, Rademaker BC, et al. Expression of a folate-binding protein in L1210 cells grown in low folate medium. Cancer Res. 1989; 49: 19591963.
  • 32
    Rosowsky A, Lazarus H, Yuan GC, et al. Effects of methotrexate esters and other lipophilic antifolates on methotrexate resistant human leukemic lymphoblasts. Biochem Pharmacol. 1980; 29: 648652.
  • 33
    Cowan KH, Jolivet JA. Methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J Biol Chem. 1984; 259: 1079310800.
  • 34
    Chango A, Emery-Fillon N, de Courcy GP,et al. A polymorphism (80G[RIGHTWARDS ARROW]A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000; 70: 310315.
  • 35
    Whetstine JR, Gifford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier and characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res. 2001; 7: 34163422.
  • 36
    Mantadakis E, Smith AK, Kamen BA. Ratio of methotrexate to folate uptake by lymphoblasts in children with B-lineage acute lymphoblastic leukemia: a pilot study. J Pediatr Hematol Oncol. 2000; 22: 403404.
  • 37
    Rots MG, Pieters R, Peters GJ, et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood. 1999; 93: 16771683.
  • 38
    Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem. 2001; 276: 3999040000.
  • 39
    Cole PD, Kamen BA, Gorlick R, et al. Effects of overexpression of γ-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res. 2001; 61: 45994604.
  • 40
    Rots MG, Willey JC, Jansen G, et al. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by standardized competitive template-based RT-PCR method. Leukemia. 2000; 14: 21662175.
  • 41
    Yang R, Sowers R, Mazza B, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma samples. Clin Cancer Res. 2003; 9: 837844.
  • 42
    Ifergan I, Meller I, Issakov J, Assaraf YG. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer. 2003; 98: 19581966.
  • 43
    Zhao R, Assaraf YG, Goldman ID. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem. 1998; 273: 78737879.
  • 44
    Merola PR, Sowers R, Yang R, et al. Reduced folate carrier sequence alterations are not common in leukemia/lymphoma samples. Proc Am Assoc Cancer Res. 2002; 43: 6061.